Neltenexine

An article about the mucolytic agent Neltenexine

Neltenexine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Neltenexine is a mucolytic agent used in the treatment of respiratory diseases characterized by excessive or thickened mucus production. It is primarily used to facilitate the clearance of mucus from the airways, lungs, bronchi, and trachea.

Mechanism of Action

Neltenexine works by breaking down the structure of mucoproteins in the mucus, thereby reducing its viscosity and elasticity. This action helps in the expectoration of mucus, making it easier for patients to clear their airways. The drug acts on the disulfide bonds within the mucus, disrupting the gel-like consistency and promoting a more fluid state.

Pharmacokinetics

Neltenexine is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily through the renal system. The onset of action is typically within 30 minutes to 1 hour after administration, with effects lasting for several hours.

Clinical Uses

Neltenexine is indicated for use in conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchitis, and other respiratory conditions where mucus hypersecretion is a problem. It is often used in conjunction with other therapies such as bronchodilators and corticosteroids.

Side Effects

Common side effects of Neltenexine include nausea, vomiting, and gastrointestinal discomfort. Rarely, it may cause allergic reactions such as rash, itching, or swelling. Patients are advised to report any severe or persistent side effects to their healthcare provider.

Contraindications

Neltenexine is contraindicated in patients with known hypersensitivity to the drug or its components. Caution is advised in patients with peptic ulcer disease or renal impairment.

Dosage and Administration

The dosage of Neltenexine varies depending on the severity of the condition and the patient's response to treatment. It is typically administered in tablet form, with doses adjusted based on clinical response and tolerability.

Related pages

• Mucolytic agent
• Chronic obstructive pulmonary disease
• Cystic fibrosis
• Bronchitis

• 

  Neltenexine